Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Change in Accured Expenses (2016 - 2025)

Rein Therapeutics has reported Change in Accured Expenses over the past 10 years, most recently at $584000.0 for Q4 2025.

  • Quarterly Change in Accured Expenses rose 126.36% to $584000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.6 million through Dec 2025, down 255.06% year-over-year, with the annual reading at -$2.6 million for FY2025, 255.06% down from the prior year.
  • Change in Accured Expenses was $584000.0 for Q4 2025 at Rein Therapeutics, up from -$34000.0 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $1.8 million in Q2 2024 and troughed at -$3.2 million in Q2 2025.
  • The 5-year median for Change in Accured Expenses is $94000.0 (2023), against an average of -$93900.0.
  • Year-over-year, Change in Accured Expenses tumbled 737.61% in 2022 and then surged 473.24% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at -$226000.0 in 2021, then tumbled by 737.61% to -$1.9 million in 2022, then skyrocketed by 105.76% to $109000.0 in 2023, then skyrocketed by 136.7% to $258000.0 in 2024, then skyrocketed by 126.36% to $584000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Change in Accured Expenses are $584000.0 (Q4 2025), -$34000.0 (Q3 2025), and -$3.2 million (Q2 2025).